Tesamorelin: FDA - Approved Research on Visceral Fat and Metabolic Health
Compound Research Guide — FDA-Approved Science · 7 min read · syntheralab.com
Tesamorelin occupies a unique position in the peptide research landscape: it is one of the few peptides in the space with full FDA approval, backed by phase 3 clinical trial data. Understanding its mechanism and documented outcomes provides a window into what rigorous peptide research can achieve.
What tesamorelin is
Tesamorelin is a synthetic 44-amino acid analogue of growth hormone-releasing hormone (GHRH). Rather than supplying exogenous growth hormone directly — which carries supraphysiological risk — tesamorelin prompts the body's own pituitary gland to release growth hormone in a pulsatile, physiologic pattern. This preserves the natural feedback mechanisms that regulate IGF-1, potentially limiting the adverse effects associated with direct GH supplementation.
FDA approval and clinical foundation
Tesamorelin received FDA approval in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This approval was based on two phase 3 clinical trials enrolling 806 HIV-infected patients with excess abdominal fat. The compound became the first FDA-approved treatment specifically for lipodystrophy — a condition characterized by abnormal fat accumulation caused by antiretroviral therapy.
Visceral fat reduction — the clinical evidence
In the pooled analysis of the two phase 3 trials, tesamorelin treatment for 26 weeks produced a 15.4% treatment effect in visceral adipose tissue reduction compared to placebo. A follow-up study at Massachusetts General Hospital showed tesamorelin significantly reduced visceral adipose tissue (mean change -34 cm² with tesamorelin vs +8 cm² with placebo, p=0.005) and additionally reduced liver fat. What makes these findings particularly notable is their specificity: subcutaneous fat remained essentially unchanged while visceral fat — the metabolically active, organ-surrounding fat associated with cardiovascular risk — was selectively reduced.
Cardiovascular and metabolic benefits
Beyond visceral fat, tesamorelin treatment significantly decreased triglycerides (-12.3% treatment effect) and the cholesterol-to-HDL ratio (-7.2% treatment effect) versus placebo in the phase 3 trials. A 2025 study examining cardiovascular risk specifically concluded that tesamorelin can lead to a significant reduction in cardiovascular disease risk among people with HIV — a population whose cardiovascular event risk is twice that of the general population.
Liver fat reduction findings
Research published in JAMA in 2014 demonstrated that tesamorelin administered for 6 months was associated not only with visceral fat reductions but also with modest reductions in liver fat — findings that were later confirmed and expanded. This hepatic component has generated considerable research interest given the prevalence of metabolic-associated liver disease.
Research Sources
Falutz et al., J Acquir Immune Defic Syndr (2010) — Phase 3 Pooled Analysis: Tesamorelin produced a 15.4% treatment effect in VAT reduction; significantly decreased triglycerides (-12.3%) and cholesterol-to-HDL ratio (-7.2%) vs placebo.
Stanley et al., JAMA (2014): Tesamorelin significantly reduced visceral adipose tissue (mean change -34 cm² vs +8 cm² placebo) and liver fat over 6 months in HIV-infected patients.
Grinspoon et al., Open Forum Infectious Diseases (2025): Tesamorelin leads to a significant reduction in cardiovascular disease risk among people with HIV.
NEJM Phase 3 Trial: Daily tesamorelin for 26 weeks decreased visceral fat and improved lipid profiles in HIV-infected patients with treatment-associated central fat accumulation.
→ Tesamorelin research kits available at syntheralab.com — the only peptide in Synthera's catalog with full FDA-approved phase 3 clinical data.
